Clinical Trial Update: Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating decitabine in combination with standard-of-care therapy for surgically resectable HPV-negative head and neck squamous cell car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hpv-negative Head and Neck Cancer

Drugs mentioned

• Dacogen (decitabine)

Snippet

Sponsor: Mayo Clinic | Conditions: Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING